DaVita's stable revenue growth of 5.2% YoY in Q2 2026 and robust cash conversion (cumulative OCF of $4.72B vs. net income of $2.15B over ten quarters) underscore operational resilience, yet the balance sheet remains strained with negative equity of -$765.1M an...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue grew 5.2% YoY to $3.6B in Q2 2026 with gross margin expanding to 32.7%, while EPS surged 55.8% to $4.02, driven by buybacks and favorable tax items.
The bullish thesis highlights improving mortality rates as a key driver for DaVita's growth and sustainability in dialysis services.
The company has potential for sustained organic volume growth, supporting long-term revenue expansion.
2026 outlook exceeded Street expectations, shifting the narrative from recovery to durable growth, reinforcing investor confidence.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $4.02+3.6% vs $3.88 | $3.6B+1.7% vs $3.5B |
Q2 2026 May 5, 2026 | $2.87+19.1% vs $2.41 | $3.4B+1.8% vs $3.4B |
Q1 2026 Feb 2, 2026 | $3.40+4.9% vs $3.24 | $3.6B+3.2% vs $3.5B |
Q4 2025 Oct 29, 2025 | $2.51-20.8% vs $3.17 | $3.4B-0.2% vs $3.4B |
With AI companies—and related chip stocks—driving much of the market's performance this year, it's understandable that some investors are hesitant to put all their trust in a burgeoning industry, no matter how much momentum it seems to have. Fortunately, a number of non-AI stocks have stood out for their strong performance throughout the first part of 2026.
DaVita HealthCare (DVA) closed the most recent trading day at $193.86, moving +1.55% from the previous trading session.
President Donald Trump has disclosed over 20,000 stock trades made over the past 12 months. The trades, which the White House says Trump has no knowledge of, span a wide range of sectors and dollar amounts.
On September 14, 2026, DaVita Inc (DVA) shares rose 4.3% to $189.32, reflecting strong momentum as the stock trades within a 52-week range of $101.00 to $247.49
Benchmark DVA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for DaVita Inc. (DVA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $183.14 | $11.76B | 19.26 | 6.46% | 5.47% | 45.96% | — | |
| $22.41 | $12.04B | 11.72 | 1.51% | 4.83% | 6.71% | — | |
| $29.40 | $265.8M | 15.00 | 33.46% | 18.47% | 11.57% | — | |
| $371.29 | $337.18B | 28.06 | 11.81% | 3.14% | 13.49% | — | |
| $374.80 | $45B | 38.09 | 10.06% | 0.88% | 6.89% | — | |
| $62.07 | $30.66B | -4.56 | 19.44% | -2.63% | -23.94% | — |
DaVita Inc. (DVA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
DaVita Inc. (DVA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Jun 8, 2026·SEC
May 5, 2026·SEC
Get notified when DVA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DaVita Inc. (DVA) stock FAQ — growth, dividends, profitability & financials explained
DaVita Inc. (DVA) reported $14.01B in revenue for fiscal year 2025. This represents a 5034% increase from $272.9M in 1996.
DaVita Inc. (DVA) grew revenue by 6.5% over the past year. This is steady growth.
Yes, DaVita Inc. (DVA) is profitable, generating $847.5M in net income for fiscal year 2025 (5.5% net margin).
DaVita Inc. (DVA) has a return on equity (ROE) of 46.0%. This is excellent, indicating efficient use of shareholder capital.
DaVita Inc. (DVA) generated $1.61B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
